AU2006275914A1 - Compositions for affecting weight loss - Google Patents

Compositions for affecting weight loss Download PDF

Info

Publication number
AU2006275914A1
AU2006275914A1 AU2006275914A AU2006275914A AU2006275914A1 AU 2006275914 A1 AU2006275914 A1 AU 2006275914A1 AU 2006275914 A AU2006275914 A AU 2006275914A AU 2006275914 A AU2006275914 A AU 2006275914A AU 2006275914 A1 AU2006275914 A1 AU 2006275914A1
Authority
AU
Australia
Prior art keywords
compound
derivative
group
agonist
gaba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006275914A
Other languages
English (en)
Inventor
Michelle S Higgin
John M Mccall
Anthony A Mckinney
Gary Tollefson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orexigen Therapeutics Inc
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of AU2006275914A1 publication Critical patent/AU2006275914A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006275914A 2005-07-27 2006-07-24 Compositions for affecting weight loss Abandoned AU2006275914A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70287705P 2005-07-27 2005-07-27
US60/702,877 2005-07-27
PCT/US2006/028875 WO2007016108A1 (en) 2005-07-27 2006-07-24 Compositions for affecting weight loss

Publications (1)

Publication Number Publication Date
AU2006275914A1 true AU2006275914A1 (en) 2007-02-08

Family

ID=37198787

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006275914A Abandoned AU2006275914A1 (en) 2005-07-27 2006-07-24 Compositions for affecting weight loss

Country Status (12)

Country Link
US (1) US20070117827A1 (cg-RX-API-DMAC7.html)
EP (1) EP1907005A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009502931A (cg-RX-API-DMAC7.html)
KR (1) KR20080042092A (cg-RX-API-DMAC7.html)
CN (1) CN101237886A (cg-RX-API-DMAC7.html)
AU (1) AU2006275914A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0613911A2 (cg-RX-API-DMAC7.html)
CA (1) CA2614539A1 (cg-RX-API-DMAC7.html)
IL (1) IL188442A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008001136A (cg-RX-API-DMAC7.html)
RU (1) RU2007147609A (cg-RX-API-DMAC7.html)
WO (1) WO2007016108A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
CA2702680A1 (en) 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
AU2009249071A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Hepatoprotectant acetaminophen mutual prodrugs
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PT3222280T (pt) 2010-12-03 2021-04-22 Nalpropion Pharmaceuticals Llc Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB201704911D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
CA3083850A1 (en) * 2017-03-28 2019-10-04 LDN Pharma Limited An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
KR101167579B1 (ko) * 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물

Also Published As

Publication number Publication date
WO2007016108A1 (en) 2007-02-08
BRPI0613911A2 (pt) 2011-02-22
JP2009502931A (ja) 2009-01-29
CN101237886A (zh) 2008-08-06
EP1907005A1 (en) 2008-04-09
US20070117827A1 (en) 2007-05-24
RU2007147609A (ru) 2009-09-10
KR20080042092A (ko) 2008-05-14
CA2614539A1 (en) 2007-02-08
MX2008001136A (es) 2008-03-13
IL188442A0 (en) 2008-04-13
WO2007016108B1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
US11278544B2 (en) Compositions for affecting weight loss
US20060058293A1 (en) Combination of bupropion and a second compound for affecting weight loss
US20070117827A1 (en) Compositions for affecting weight loss
US20060100205A1 (en) Compositions for affecting weight loss
EP1870096A2 (en) Compositions for affecting weight loss
HK1157630A (en) Compositions for affecting weight loss comprising an opioid antagonist and bupropion
HK1157630B (en) Compositions for affecting weight loss comprising an opioid antagonist and bupropion
HK1088850B (en) Compositions for affecting weight loss

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted